MedPath

Angiotensin II

Generic Name
Angiotensin II
Brand Names
Giapreza
Drug Type
Biotech
CAS Number
4474-91-3
Unique Ingredient Identifier
M089EFU921
Background

Angiotensin II is under investigation for the treatment of Sepsis, Septic Shock, Diabetes Mellitus, and Acute Renal Failure. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy.

As of December 21, 2017 the FDA approved La Jolla Pharmaceutical's Giapreza (angiotensin II) Injection for Intravenouse Infusion for the indication of acting as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. The novelty of the medication lies in the fact that it is the first and only use of synthetic human angiotensin II to help maintain body blood pressure.

Shock is the inability to maintain blood flow to vital tissues and the potential resultant organ failure and death within hours, no matter young or o ld. As distributive shock is the most common type of shock in the inpatient setting and affects up to one third of patients in the intensive care unit, the FDA determined that there is a need for treatment options for critically ill hypotensive patients who do not adequately respond to currently available therapies.

Indication

Angiotensin II is a vasoconstrictor indicated for increasing blood pressure in adults with septic or other distributive shock .

Associated Conditions
Hypotension
Clinical Trials
Related News

EMA Designates Allopurinol as First Orphan Drug for Marfan Syndrome

• The European Medicines Agency has designated allopurinol as the first orphan drug for Marfan syndrome, a rare connective tissue disease affecting approximately 7 in 100,000 people in the European Union. • Researchers from the University of Barcelona, IDIBAPS, and CIBERER have demonstrated allopurinol's potential to halt and prevent aortic aneurysms in animal models, with international clinical trials in patients planned for the future. • This repurposing of allopurinol, currently used for gout treatment, represents a significant advancement for Marfan syndrome patients who currently have no curative options beyond limited palliative treatments and high-risk surgical interventions.

Secretome Therapeutics Initiates Phase 1 Trial of Novel Cell Therapy STM-01 for Heart Failure

• Secretome Therapeutics has dosed the first patient in a Phase 1 trial evaluating STM-01, an allogeneic neonatal cardiac progenitor cell therapy for heart failure with preserved ejection fraction (HFpEF). • The FDA recently granted Fast Track designation to STM-01, recognizing the critical need for innovative therapies in HFpEF, a condition that comprises over 50% of all heart failure diagnoses with limited treatment options. • Preclinical studies showed STM-01 significantly reduced inflammation at cellular and molecular levels in HFpEF models, resulting in improved cardiac function and exercise tolerance.

FDA Approves First Liquid Losartan Formulation for Hypertension Treatment

• Scienture Holdings announced FDA approval of Arbli™ (losartan potassium) Oral Suspension, the first and only ready-to-use liquid losartan formulation in the U.S. market for treating hypertension in patients over 6 years old. • The novel formulation addresses significant unmet needs for patients requiring liquid medications, eliminating risks associated with crushing tablets and providing consistent dosing with an 18-month shelf life at room temperature. • Arbli™ is indicated for hypertension treatment, stroke risk reduction in patients with left ventricular hypertrophy, and diabetic nephropathy management, with commercial launch expected in Q3 2025.

Ionis and Ono Forge $940 Million Deal for Sapablursen in Polycythemia Vera Treatment

• Ionis Pharmaceuticals has licensed sapablursen, an RNA-targeted medicine for polycythemia vera, to Ono Pharmaceutical in a deal worth up to $940 million including $280 million upfront. • Sapablursen, currently in Phase 2 trials, has received FDA Fast Track and Orphan Drug designations and works by increasing hepcidin production to regulate iron homeostasis in PV patients. • Ono will gain exclusive global rights for development and commercialization, while Ionis will complete the ongoing IMPRSSION study before transferring responsibilities.

FDA Approves Zevtera for S. aureus Bacteremia, Marking First New Treatment in 15 Years

• Basilea Pharmaceutica's Zevtera (ceftobiprole) receives FDA approval for three indications, becoming the first beta-lactam antibiotic approved for Staphylococcus aureus bacteremia. • The approval addresses a significant medical need, with approximately 120,000 S. aureus bloodstream infections occurring annually in the US according to CDC data. • The drug's approval includes coverage for antimicrobial-resistant infections, particularly MRSA, targeting a market projected to reach $5.5 billion by 2030.

SGLT2 Inhibitors Show Promise in Managing Chronic Kidney Disease in Real-World Settings

A recent study highlights the effectiveness and safety of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in managing chronic kidney disease (CKD), showing a significant reduction in the risk of major adverse kidney events (MAKEs) compared to traditional RAAS blockade therapy. The study, conducted in a real-world setting, supports the broader application of SGLT2i in CKD management, regardless of diabetic status, aligning with the 2024 KDIGO guidelines.

Mineralys Therapeutics' Lorundrostat Advances to Phase 2 for Obstructive Sleep Apnea and Hypertension

• Mineralys Therapeutics' lorundrostat receives FDA clearance for a Phase 2 trial targeting obstructive sleep apnea (OSA) in hypertensive patients. • The trial aims to assess lorundrostat's efficacy in reducing upper airway obstruction and nocturnal hypertension in moderate-to-severe OSA. • The Phase 2 study is set to commence in Q1 2025, evaluating 50mg of lorundrostat daily in approximately 40 participants. • Mineralys' Explore-CKD Phase 2 trial, evaluating lorundrostat for hypertension in CKD patients with albuminuria, has completed enrollment.

ARBs' Antihypertensive Effects Linked to Gut Microbiota Modulation

• A recent study in iMeta reveals that angiotensin receptor blockers (ARBs) may lower blood pressure by modulating gut microbiota composition. • Fecal microbiota transplantation (FMT) experiments showed that gut microbiota from ARB-treated hypertensive patients enhanced the drugs' blood pressure-lowering effects. • ARBs were found to alter the expression of circadian rhythm-related genes by changing gut microbiota, offering insights into hypertension and circadian rhythm disorders. • The research suggests personalized hypertension treatments based on microbiome analysis could optimize ARB efficacy by targeting specific microorganisms or metabolites.

Eravacycline Shows Sustained Antimicrobial Activity Against Resistant Bacteria in vitro

• Two in vitro studies presented at IDWeek 2024 demonstrate eravacycline's consistent antimicrobial activity against drug-resistant bacteria. • Eravacycline showed high susceptibility (98.13%) against Carbapenem-resistant _Acinetobacter baumannii_ (CRAB) using ChinaCAST breakpoint of 1 µg/mL. • A global study of 23,127 isolates showed eravacycline maintained high susceptibility against major Gram-positive and Gram-negative bacteria from 2018-2022. • Everest Medicines is committed to further exploring eravacycline's rational use in treating complex infections amid rising antimicrobial resistance.

Angiotensin II and Thromboembolism Risk Re-evaluated in Critical Care

• A systematic review suggests no consistent association between angiotensin II therapy and increased thromboembolic events, challenging previous concerns. • The review highlights variations in diagnostic processes and reporting methods as potential sources of discrepancies in thromboembolism event data. • Clinical heterogeneity across studies, including patient populations and concomitant treatments, complicates the assessment of thromboembolic risks with angiotensin II. • Future research should focus on standardized definitions, early angiotensin II initiation, and the impact of co-interventions to optimize therapy and safety.

Genetic Variants Influence Amlodipine Response in Pakistani Population, Study Finds

• A pharmacogenomic study in Pakistan reveals that genetic polymorphisms influence the effectiveness of amlodipine, a common hypertension drug. • The study identifies specific variants in genes like CACNA1C and CACNA1D that are associated with better blood pressure control in patients treated with amlodipine. • A variant in the ACE gene was linked to poorer blood pressure control, suggesting that genetic testing could help personalize hypertension treatment. • These findings highlight the potential for pharmacogenomics to improve hypertension management by tailoring drug choices based on individual genetic profiles.

Swissmedic Approves Filspari (sparsentan) for IgA Nephropathy

• Swissmedic grants temporary marketing authorization for Filspari to treat IgA nephropathy in adults with specific urine protein excretion levels. • The approval is based on Phase 3 PROTECT trial results, demonstrating statistically significant and clinically meaningful outcomes. • Filspari, a once-daily oral medication, targets kidney damage directly and offers a non-immunosuppressive alternative to RASi treatments. • CSL Vifor and Travere Therapeutics collaborate to provide access to this innovative treatment option for the Swiss IgAN community.

Dimerix's First Patient Completes Phase 3 Trial and Enters DMX-200 Open Label Extension Study for Kidney Disease

• Dimerix has enrolled the first patient into the Open Label Extension (OLE) study for its kidney disease drug candidate DMX-200 after completing the ACTION3 Phase 3 clinical trial. • The OLE study allows patients who have successfully completed the ACTION3 Phase 3 clinical trial to start or continue a two-year treatment of DMX-200 in an unblinded setting. • The OLE study will collect additional long-term data, such as safety and tolerability, to support future potential regulatory filings for DMX-200. • Interim analysis showed DMX-200 outperformed placebo in reducing proteinuria, with the Independent Data Monitoring Committee affirming no safety concerns.

FDA Grants Full Approval to Travere's Filspari for IgA Nephropathy

• The FDA granted full approval to Travere Therapeutics' Filspari (sparsentan) for IgA nephropathy, allowing broader use for patients at risk of disease progression. • The approval was based on the PROTECT study, which demonstrated Filspari significantly slowed kidney function decline over two years compared to irbesartan. • Filspari is now positioned as a foundational, non-immunosuppressive treatment option, potentially replacing the current standard of care for IgAN patients. • The label update removes a specific urine protein level requirement, expanding the eligible patient population and increasing Filspari's market potential.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy